Brief: Ocuphire Pharma Inc - Issuance Extends Nyxol's U.S. Patent Protection From 2034 Into 2039 For RM Indication

Opus Genetics

03/08/2022 13:49

Aug 3 (Reuters) - Ocuphire Pharma Inc  OCUP.O :
    * OCUPHIRE EXTENDS U.S. PATENT PROTECTION FOR LATE-STAGE
DRUG
CANDIDATE NYXOL® FOR REVERSAL OF MYDRIASIS BY FIVE MORE YEARS
INTO 2039 WITH NEW PATENT ISSUANCE
    * OCUPHIRE PHARMA INC - ISSUANCE EXTENDS NYXOL'S U.S. PATENT
PROTECTION FROM 2034 INTO 2039 FOR RM INDICATION
    * OCUPHIRE PHARMA INC - GROWING PATENT ESTATE ELIGIBLE FOR
FDA
ORANGE BOOK LISTING
    * OCUPHIRE PHARMA INC - ON TRACK TO FILE NDA FOR NYXOL IN
FIRST
INDICATION RM IN LATE 2022
    * OCUPHIRE PHARMA INC - POTENTIAL SECOND HALF 2023 APPROVAL
AS
ONLY EYE DILATION REVERSAL DROP
    * OCUPHIRE PHARMA INC - IF APPROVED, NYXOL COULD BE LAUNCHED
IN
SECOND HALF OF 2023

Source text for Eikon:  ID:nGNX72BP1g 
Further company coverage:  OCUP.O